S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer

NCT ID: NCT01426646

Last Updated: 2012-01-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 218 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2016-09-30

Brief Summary

Although there has been some progress in chemotherapy for metastatic gastric cancer, no standard regimen of adjuvant chemotherapy is available, and many clinical trials have produced contradictory results. The majority of randomized clinical trials studying adjuvant chemotherapy in gastric cancer have been underpowered, involved low-volume centers, or used ineffective chemotherapy regimens. As a result, well-designed multicenter trials are still needed. The ACTS-GC trial, which demonstrated the efficacy of S-1 for stage II-III gastric cancer patients who underwent curative resection with extended lymph-node dissection (D2), may be valid in countries where D2 surgery is considered the standard of care. S-1 improved the 3-year overall survival from 70.1% for surgery alone to 80.1%. However, 3-year overall survival in stage IIIA and stage IIIB patients receiving S-1 were 77.4% and 63.4%, respectively, which are less satisfactory compared to the rate for stage II (90.7%). Based on the unsatisfactory outcome among later stage patients in the ACTS-GC adjuvant trial, further investigation is needed for more effective postoperative treatment of patients with stage IIIB and IV (M0) cancer. Therefore, the researchers investigated the efficacy and safety of S-1 versus S-1 plus cisplatin as adjuvant chemotherapy in patient with curatively resected gastric adenocarcinoma.

Detailed Description

This controlled study is designed to evaluate the efficacy of S-1 on survival compared with S-1 plus cisplatin. Patients will be randomly assigned to receive either surgery followed by treatment with S-1 plus cisplatin or surgery followed by treatment with S-1 within 42 days after curative resection. To assess the efficacy, data on recurrence and survival will be collected from the time of enrollment until 5 years after surgery. To evaluate safety, data on adverse events will be collected from the time of enrollment until 1 year after surgery.

Conditions

Gastric Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

S-1 treatment

S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.

Group Type: EXPERIMENTAL

S-1

Intervention Type: DRUG

S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.

S-1 plus cisplatin treatment

S-1 plus cisplatin every 3 weeks, A total of eight cycles

• S-1: 40mg/m2 orally twice daily (days 1-14)
• Cisplatin: 60mg/m2 IV on day 1

Group Type: EXPERIMENTAL

S-1 plus cisplatin

Intervention Type: DRUG

S-1 plus cisplatin every 3 weeks, a total of eight cycles

• S-1: 40mg/m2 orally twice daily (days 1-14)
• Cisplatin: 60mg/m2 IV on day 1

Interventions

S-1

S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.

Intervention Type: DRUG

S-1 plus cisplatin

S-1 plus cisplatin every 3 weeks, a total of eight cycles

• S-1: 40mg/m2 orally twice daily (days 1-14)
• Cisplatin: 60mg/m2 IV on day 1

Intervention Type: DRUG

Other Intervention Names

TS-1; TS-1; cisplatin

Eligibility Criteria

Inclusion Criteria

1. 18-70 years

2. Histologically proven adenocarcinoma of the stomach

3. Curative D2 lymphadenectomy resection for gastric cancer, who can be randomized to either study arm within 6 weeks after surgery

4. Stage II, III and IV (M0)(AJCC 7th edition)

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

6. No prior chemotherapy or radiotherapy

7. Adequate bone marrow, renal, and liver function

Exclusion Criteria

1. Pregnant or lactating women.

2. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-child bearing potential.

3. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.

4. Any evidence of metastatic disease (including presence of tumor cells in the ascites).

5. Previous cytotoxic chemotherapy, radiotherapy or immunotherapy except corticosteroids, for the currently treated gastric cancer.

6. Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery.

7. History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.

Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 12 months.

8. Lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome likely to influence absorption of capecitabine, or inability to take oral medication.

9. Organ allografts requiring immunosuppressive therapy.

10. Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.

11. Prior unanticipated severe reaction to fluoropyrimidine therapy (with or without documented dihydropyrimidine dehydrogenase (DPD) deficiency) or patients with known DPD deficiency.

Hypersensitivity to platinum compounds or any of the components of the study medications.

12. Received any investigational drug or agent/procedure, i.e. participation in another trial, within 4 weeks before randomization.

13. Blood transfusions or growth factors to aid hematologic recovery within 2 weeks prior to study treatment start.

14. Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or chemically related analogues, such as brivudine.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kyungpook National University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Byung Woog Kang

Professor(full time instructor)

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Wansik Yu, Professor

Role: PRINCIPAL_INVESTIGATOR

Kyungpook National University Hospital

Locations

Donga university hospital

Busan, , South Korea

Site Status: RECRUITING

Ulsan University Hospital

Ulsan, , South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Byung Woog Kang, Professor

Role: CONTACT

bwkang@knu.ac.kr

+82-10-9216-2633

Facility Contacts

Hyuk-Chan Kwon, Professor

Role: primary

Jin Ho Baek, Professor

Role: primary

Other Identifiers

ACSPGC-01

Identifier Type: -

Identifier Source: org_study_id